课题基金 / 基金详情

Optimization and characterization of expanded CD56bright regulatory natural killer cells for the therapy of chronic graft-versus-host disease.

Optimization and characterization of expanded CD56bright regulatory natural killer cells for the therapy of chronic graft-versus-host disease.
用于治疗慢性移植物抗宿主病的扩展 CD56bright 调节性自然杀伤细胞的优化和表征。
批准号：
457612
负责人：
Lauener Madeline
金额：
$10.93万
依托单位：
University of British Columbia
依托单位国家：
加拿大
项目类别：
Studentship Programs
财政年份：
2021
资助国家：
加拿大
项目状态：
已结题
起止时间：
2021-11-01 至 2024-11-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=457612&lang=en
关键词：
Cd56bright Natural Killer Cells Cell Culture Cell Therapy Chronic Graft-Versus-Host Disease Flow Cytometry Graft-Versus-Host Disease Hematopoietic Stem Cell Transplantation Immunotherapy Regulatory Natural Killer Cells

项目摘要

项目成果

Lauener Madeline的其他基金

相似基金

相关文献

中文摘要
翻译
造血干细胞移植（HSCT）是将供体免疫系统输注到受者体内的一种重要的基于免疫的治疗方法，用于高危和复发性血癌患者。然而，HSCT被认为是愈合风险的增加
英文摘要
Hematopoietic Stem Cell Transplantation (HSCT), the infusion of a donors immune system into a recipient, is an important immune-based therapy for patients with high-risk and recurring blood cancers. However, HSCT is attributed to an increased risk of heal
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Optimization and characterization of expanded CD56bright regulatory natural killer cells for the therapy of chronic graft-versus-host disease.
Optimization and characterization of expanded NKreg cells for therapy of chronic graft-versus-host disease
  • 批准号：
    449621
  • 项目类别：
    Studentship Programs
  • 资助金额：
    $1.27万
  • 财政年份：
    2020
  • 负责人：
    Lauener Madeline
  • 依托单位：
    University of British Columbia
海外基金